Inventum Genetics GmbH

Technology Platforms


Inventum Genetics GmbH was incorporated in 2019 in Mainz, Germany.

Inventum Genetics GmbH is dedicated to identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data. To this end, the company collaborates with the Center for Human Genetics at the Philipps University of Marburg (Germany). The focus is on the genetic analysis of biological processes. The first project deals with the cellular response to DNA damage, a central mechanism of neurodegenerative and oncological diseases. The global market for drugs targeting DNA repair mechanisms is expected to reach $25 billion by 2030.

For more information, please visit:

Melden Sie sich für unsere Medienmitteilungen an

Wir berichten regelmässig über die geschäftliche Entwicklung der Xlife Sciences AG und unserer Projektgesellschaften.